Designates October of each year as "Opioid Abuse Prevention Month."
Impact
The designation of October as 'Opioid Abuse Prevention Month' seeks to unify state efforts in raising awareness and enhancing public education regarding opioid addiction. It aims to inform public officials, community leaders, and citizens about the dangers of opioid misuse. Furthermore, the resolution calls for the governor to annually issue a proclamation encouraging appropriate observances, activities, and programs to mark the month, ensuring that the issue remains a focal point of public health discussions and initiatives.
Summary
SJR83 is a Joint Resolution introduced in New Jersey to designate October of each year as 'Opioid Abuse Prevention Month.' The resolution aims to promote education about the signs and consequences of opioid abuse, recognize efforts to combat this epidemic, and encourage support for those affected by opioid misuse. The bill emphasizes the urgency of addressing the growing crisis of opioid dependence, particularly given the alarming statistics surrounding opioid-related overdose deaths and addiction rates in New Jersey.
Contention
While the resolution itself may not present significant points of contention, it brings to light the broader public health issues related to opioid abuse in New Jersey. Stakeholders might debate the effectiveness of awareness campaigns versus direct intervention strategies, funding for addiction treatment programs, and the role of healthcare providers in preventing prescription drug misuse. Given the social and economic impacts of the opioid crisis, discussions could also arise about the balance of punitive measures against substance abuse versus promoting recovery and rehabilitation.
Designates October of each year as "Menopause Awareness Month," October 11 of each year as "Perimenopause Day," and October 18 of each year as "Postmenopause Day" in New Jersey.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.